Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma

We report the case of a 70-year-old woman who developed COVID-19 immediately before CAR-T therapy for high-grade B-cell lymphoma. She received Tixagevimab-Cilgavimab chemotherapy and radiation therapy but never achieved remission. She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term molnupiravir. On day 28 post-infection, lymphodepleting chemotherapy was restarted after a negative polymerase chain reaction (PCR) test was confirmed. The patient did not experience recurrence of COVID-19 symptoms or severe cytokine release syndrome. Based on the analysis and comparison of the previous reports with this case, we believe that CAR-T therapy should be postponed until a negative PCR test is confirmed. In addition, Tixagevimab-Cilgavimab and long term direct-acting antiviral agent treatment can be effective prophylaxis for severe COVID-19 and shortening the duration of infection.PMID:38349446 | DOI:10.1007/s12185-024-03711-5

Source: International Journal of Hematology - February 13, 2024 Category: Hematology Authors: Kenta Hayashino Keisuke Seike Kanako Fujiwara Kaho Kondo Chisato Matsubara Toshiki Terao Wataru Kitamura Chihiro Kamoi Hideaki Fujiwara Noboru Asada Hisakazu Nishimori Daisuke Ennishi Keiko Fujii Nobuharu Fujii Ken-Ichi Matsuoka Yoshinobu Maeda Source Type: research